Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Colorectal cancer, drawn from the whole corpus: 401 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
MSS metastatic disease is immunotherapy-resistant.
Background: Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), Organ tropism: seed and soil, Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Early-onset CRC causes unknown.
KRAS G12D (most common) undrugged.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
Microsatellite-stable metastatic disease (95%) remains immunotherapy-resistant; liver metastases actively suppress systemic immunity.
Background: Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), Organ tropism: seed and soil, Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
KRAS G12D and G12V, the most common drivers, have no approved inhibitor; RAS(ON) inhibitors are the first credible attempt.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
Early-onset colorectal cancer is rising ~2% per year with no established cause and no screening before 45.
Background: Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
ctDNA identifies who will relapse but no escalation strategy has changed outcomes (ALTAIR negative).
Background: Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Anti-EGFR resistance is universal; rechallenge and ctDNA-guided sequencing are unproven in phase 3.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Rectal cancer organ preservation lacks randomised comparison against surgery in pMMR disease.
Peritoneal metastases respond poorly to systemic therapy; HIPEC with oxaliplatin failed (PRODIGE 7).
Background: Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), Organ tropism: seed and soil, Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Disparities: screening uptake and outcomes differ sharply by race, income, and geography.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 99 changes by month →When this page itself was last checked or edited.
Colorectal cancer screening in average-risk adults aged 45 and older
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Breakthrough Therapy designation, dMMR locally advanced rectal cancer (organ preservation)